RxDoctor Payments Data

Lucy Sun, MD

Ophthalmology · Fresh Meadows, NYNPI 1245684364

Payments from drug & device makers

$2,363in general payments, 2019–2025

Across 90 payments — averaging $26.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$369
  • Mallinckrodt Hospital Products Inc.$296
  • AbbVie$242
  • Oyster Point Pharma, Inc.$230
  • Sun Pharmaceutical Industries Inc.$217
  • Biotissue Holdings Inc.$205
  • plus $805 from 16 others

What the payments were for

  • Food & beverage$2,363100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,363 in reported general payments places this provider in the 60th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York

Medicare billing

Part B allowed, 2024
$221,311
Medicare patients
631
Services billed
1,720

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine44$58,428
XiidraLifitegrast17$26,092
ProlensaBromfenac Sodium73$26,028
LumiganBimatoprost40$16,334
Prednisolone Acetate298$8,556
MoxifloxacinMoxifloxacin Hcl208$4,680
Tobramycin-DexamethasoneTobramycin/Dexamethasone69$3,476
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol21$3,332
Bromfenac Sodium12$3,023
Latanoprost219$2,633
SimbrinzaBrinzolamide/Brimonidine Tart13$2,596
Loteprednol Etabonate19$2,523
Ketorolac Tromethamine74$1,307
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat98$1,257
Timolol Maleate85$611

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$242$74,76284 claims
Bausch & Lomb Americas Inc.Xiidra$90$26,09217 claims
AlconSimbrinza$369$2,59613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,587 ophthalmology providers in New York.

Other ophthalmology in Fresh Meadows

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →